Brief: Cyclerion Therapeutics Announces Praliciguat Topline Phase 2 Results In Diabetic Nephropathy

Korsana Biosciences

30/10/2019 13:29

Oct 30 (Reuters) - Cyclerion Therapeutics Inc  CYCN.O :
    * CYCLERION THERAPEUTICS ANNOUNCES PRALICIGUAT TOPLINE PHASE
2
RESULTS IN DIABETIC NEPHROPATHY
    * CYCLERION THERAPEUTICS INC - STUDY DID NOT REACH
STATISTICAL
SIGNIFICANCE ON PRIMARY ENDPOINT
    * CYCLERION THERAPEUTICS INC - COMPANY INTENDS TO PURSUE
OUT-LICENSE OF PRALICIGUAT FOR LATE-STAGE DEVELOPMENT
    * CYCLERION THERAPEUTICS INC - POSITIVE TRENDS ON PRIMARY
AND
SECONDARY ENDPOINTS INDICATE PROFILE THAT MERITS FURTHER
INVESTIGATION
    * CYCLERION THERAPEUTICS INC - PRALICIGUAT WAS GENERALLY
WELL
TOLERATED, AND SAFETY PROFILE WAS SUPPORTIVE OF CONTINUED
DEVELOPMENT
    * CYCLERION THERAPEUTICS - DURING STATISTICAL VALIDATION,
DATA
FROM 1 CLINICAL TRIAL SITE WERE FOUND TO BE INCONSISTENT WITH
OVERALL STUDY POPULATION
    * CYCLERION THERAPEUTICS - AT SITE WITH INCONSISTENT DATA,
GREATER
PERCENT OF PATIENTS ASSIGNED TO PRALICIGUAT HAD UNDETECTABLE
PRALICIGUAT PLASMA CONCENTRATIONS
    * CYCLERION THERAPEUTICS INC - AS OF SEPTEMBER 30, 2019,
CYCLERION
HAD APPROXIMATELY $125 MILLION OF CASH, CASH EQUIVALENTS AND
RESTRICTED CASH
    * CYCLERION THERAPEUTICS - ANTICIPATES THAT CASH, CASH
EQUIVALENTS
& RESTRICTED CASH AS OF SEPT. 30 WILL BE SUFFICIENT TO FUND ITS
OPERATIONS THROUGH Q1 2021

Source text for Eikon:  ID:nGNX9r6FgT 
Further company coverage:  CYCN.O 

 ((Reuters.Briefs@thomsonreuters.com;))